Impaired expression of type i and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Chandra, Partha K ^a   Gunduz, Feyza ^a   Hazari, Sidhartha ^a   Kurt, Ramazan ^a   Panigrahi, Rajesh ^a   Poat, Bret ^a   Bruce, David ^b   Cohen, Ari J ^b   Behorquez, Humberto E ^b   Carmody, Ian ^b   Loss, George ^b   Balart, Luis A ^a   Wu, Tong ^a   Dash, Srikanta ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b OCHSNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; AUTOPHAGY PROTEIN 5; BECLIN 1; BINDING IMMUNOGLOBULIN PROTEIN; BINDING PROTEIN; CONCENTRATIVE NUCLEOSIDE TRANSPORTER 1; CORE PROTEIN; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GAMMA INTERFERON RECEPTOR 1; INITIATION FACTOR 2ALPHA; INOSITOL REQUIRING ENZYME 1 ALPHA; INTERFERON ALPHA RECEPTOR 1; MEMBRANE PROTEIN; PHOSPHATIDYLETHANOLAMINE; UNCLASSIFIED DRUG; VIRUS RNA; ALCOHOL; ALPHA BETA INTERFERON RECEPTOR; FATTY ACID; INTERFERON RECEPTOR; INTERFERON RECEPTOR, TYPE II; RIBAVIRIN;

ARTICLE; AUTOPHAGY; CELL CULTURE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENDOPLASMIC RETICULUM STRESS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL; LIVER CIRRHOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRAL CLEARANCE; VIROGENESIS; VIRUS DETECTION; VIRUS REPLICATION; WESTERN BLOTTING; BIOPSY; CHRONIC HEPATITIS C; DRUG EFFECTS; HEPACIVIRUS; LIVER; METABOLISM; PATHOLOGY; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL; VIROLOGY;

HEPATITIS C VIRUS;

AUTOPHAGY; BIOLOGICAL TRANSPORT; BIOPSY; CELLS, CULTURED; DOWN-REGULATION; ENDOPLASMIC RETICULUM STRESS; ETHANOL; FATTY ACIDS, NONESTERIFIED; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; LIVER; LIVER CIRRHOSIS; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON; RIBAVIRIN; VIRUS REPLICATION;

EID: 84907487818     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108616     Document Type: Article

References (43)

1. Lemoine M, Thursz M (2014) Hepatitis C, a global issue: Access to care and new therapeutic and preventive approaches in resource-constrained areas. Seminar Liver Dis 34: 89-97.
2. Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancer Infect Dis 5: 558-567.
3. Thomas DL, Seeff LB (2005) Natural history of hepatitis C. Clin Liver Dis 9: 383-398.
4. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, et al. (2013) Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 158: 329-337.
5. Toshikuni N, Arisawa T, Tsutsumi M (2014) Hepatitis C-related liver cirrhosis-stretegies for the prevention of hepatic decompensation, hepatocarcinogenesis and mortality. World J Gastroenterol 20: 2876-2887.
6. Forestier N, Zeuzem S (2012) Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders. Liver Int 32: 44-50.
7. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago S, et al. (2011) Telaprevir for retreatment of HCV infection. N Eng J Med 364: 2417-2428.
8. Asselah T, Estrabaud E, Bieche I, lapalus M, De Muynck S, et al. (2010) Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver International 30: 1259-1269.
9. Zhu Y, Chen S (2013) Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. World J Gastroenterol 19: 8963-8973.
10. Booth DR, Ahlenstiel G, George J (2012) Pharmacogenomics of hepatitis C infections: personalizing therapy. Genome Med 4: 99.
11. Bota S, Sporea I, Sirli R, Popescu A, Neghina AM, et al. (2013) Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review. World J Hepatol 5: 120-126.
12. Wright TL (2002) Treatment of patients with hepatitis C and cirrhosis. Hepatology 36: S185-S192.
13. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hoffmann WP, et al. (2007) Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 147: 677-684.
14. Darnell JE Jr., Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1421.
15. Lemon SM (2010) Induction and evasion of innate antiviral responses by hepatitis C virus. J Biol Chem 285: 22741-22747.
16. Hazari S, Chandra PK, Poat B, Datta S, Garry RF, et al. (2010) Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway. Virology J 7: 36-52.
17. Datta S, Hazari S, Chandra PK, Samara M, Poat B, et al. (2011) Mechanisms of HCV's resistance to IFN-alpha in cell culture involves expression of functional IFN-alpha receptor 1. Virology J 8: 351-369.
18. Chandra PK, Bao L, Song K, Aboulnasr FM, Baker DP, et al. (2014) HCV infection selectively impairs Type I but not the Type III IFN signaling. Am J Pathol 184: 214-229.
19. Liu S, Nelson CA, Xiao L, Lu L, Davis DR, et al (2011) Measuring antiviral activity of benzimidazole molecules that alters IRES RNA structure with an infectious hepatitis C virus chimera expressing Renilla Luciferase. Antiviral Res 89: 54-63.
20. Chandra PK, Kundu AK, Hazari S, Chandra S, Bao L, et al. (2012) Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes. Mol Ther 20: 1724-1736.
21. Gerber MA, Sheih C, Shim K-S, Thung SN, Demetris AJ, et al. (1992) Detection of replicative hepatitis C virus sequences in hepatocellular carcinoma. Am J Pathol 141: 1271-1277.
22. Gunduz F, Mallikarjun C, Balart LA, Dash S (2014) Interferon alpha induced intrahepatic pSTAT1 inversely correlates with serum HCV RNA levels in chronic HCV infection. Exp Mol Pathol 96: 36-41.
23. Bukh M (2008) Direct infection and replication of naturally occurring hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures. PLoS One 3: e2660.
24. Gondeau C, Briolotti P, Razafy F, Duret C, Rubbo PA, et al. (2013) In vitro infection of primary human hepatocytes by HCV-positive sera: insight on a highly relevant model. Gut 0: 1-11.
25. Steenbergen RHG, Joyce MA, Thomas BS, Jones D, Law J, et al. (2013) Human serum leads to differentiation of human hepatoma cells, restoration of very-low-density lipoprotein secretion, and a 1000-fold increase in HCV JFH type 1 titers. Hepatology 58:1907-1917.
26. Dash S, Rege TA, Tsuji H, Gaglio P, Garry RF, et al. (2000) HCV RNA levels in hepatocellular carcinomas and adjacent non-tumorous livers. J Virol Methods 90: 15-23.
27. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358: 958-965.
28. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 347: 975-82.
29. Roffi L, Colloredo G, Pioltelli P, Bellati G, Pozzpi M, et al. (2008) Peginterferon alfa-2b plus ribavirin: an efficacious and well tolerated regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antiviral Ther 13: 663-673.
30. Liu J, HuangFu WC, Kumar KG, Qian J, Casey JP, et al. (2009) Virus-induced unfolded protein response attenuates anti-viral defenses via phosphorylation-dependent degradation of Type I interferon receptor. Cell Host Microbe 5: 72-83.
31. Malhi H, Kaufman RJ (2011) Endoplasmic reticulum stress in liver disease. J Hepatol 54:795-809.
32. Czaja MJ, Ding W-X, Donohue TM (2013) Functions of autophagy in normal and diseased liver. Autophagy 9: 1131-1158.
33. Asselah T, Bieche I, Mansouri A, laurendeau I, Cazals-Hatem D, et al. (2010) In vivo hepatic endoplasmic stress in patients with chronic hepatitis C. J Pathol 221: 264-274.
34. Ait-Goughoulte M, Kanda T, Meyer K, Ryerse JS, Ray RB, et al. (2008) Hepatitis C Virus genotype 1a growth and induction of autophagy. J Virol 82: 2241-2249.
35. Shuda M, Kondoh N, Imazeki N, Tanaka K, Okada T, et al. (2003) Activation of the ATG6, XBP1 and GRP78 genes in human hepatocellular carcinoma: a possible involvement of the ER-stress pathway in hepatocarcinogenesis. J Hepatol 38: 605-614.
36. Su IJ, Wang HC, Wu HC, Huang WY (2008) Ground glass hepatocytes contain pre-S mutants and represent preneoplastic lesions in chronic HBV infection. J Gastroenterol Hepatol 23:1169-1174.
37. Rautou PE, Cazals-Hatem D, Feldmann G, Mansouri A, Grodet A, et al. (2011) Changes in autophagy response in patients with chronic hepatitis C virus infection. Am J Pathol 178: 2708-2715.
38. Lin JH, Walter P, Benedict Yen TS (2008) Endoplasmic Reticulum Stress in Disease Pathogenesis. Annu Rev Path Mech Dis 3: 399-425.
39. Soza A, Heller T, Ghany M, Lutchman G, Liang TJ, et al. (2005) Pilot study of interferon gamma for hepatitis C. J Hepatol 43: 67-71.
40. Zeuzem S (2004) Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 140:370-381.
41. Han D, Lerner AG, Vande Walle L, Upton JP, et al. (2009) IRE1 alpha kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates. Cell 138: 562-575.
42. Li X, Yan J, Wang L, Xiao F, Yang Y, et al. (2013) Beclin1 inhibition promotes autophagy and decreases gemcitabine-induced apoptosis in Miapaca2 pancreatic cancer cells. Cancer Cell Int 13: 13-26.
43. Pietrocola F, Izzo V, Niso-Santano M, Vacchelli E, Gulluzzi L, et al. (2013) Regulation of autophagy by stress-responsive transcription factors. Semin Cancer Biol 23: 310-322.